Private Asset Management Inc. increased its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 190.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 86,975 shares of the biotechnology company’s stock after purchasing an additional 57,050 shares during the quarter. Private Asset Management Inc. owned approximately 0.14% of Heron Therapeutics worth $1,574,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of the stock. Rubric Capital Management LP boosted its holdings in shares of Heron Therapeutics by 11.8% during the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after purchasing an additional 200,000 shares during the period. Perceptive Advisors LLC acquired a new stake in Heron Therapeutics in the third quarter valued at approximately $5,329,000. Janus Henderson Group PLC lifted its stake in Heron Therapeutics by 2.2% in the third quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock valued at $93,145,000 after acquiring an additional 126,039 shares during the last quarter. Jane Street Group LLC acquired a new stake in Heron Therapeutics in the third quarter valued at approximately $223,000. Finally, Alyeska Investment Group L.P. lifted its stake in Heron Therapeutics by 9.5% in the third quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock valued at $12,188,000 after acquiring an additional 65,260 shares during the last quarter. Institutional investors and hedge funds own 98.78% of the company’s stock.
Shares of Heron Therapeutics Inc (HRTX) remained flat at $$18.55 during trading on Friday. The company’s stock had a trading volume of 594,436 shares, compared to its average volume of 981,059. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics Inc has a 52-week low of $12.21 and a 52-week high of $19.55. The firm has a market capitalization of $1,000.00, a price-to-earnings ratio of -4.89 and a beta of 2.12.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. equities research analysts anticipate that Heron Therapeutics Inc will post -3.39 EPS for the current fiscal year.
HRTX has been the subject of a number of analyst reports. Noble Financial reiterated a “buy” rating and issued a $24.00 target price on shares of Heron Therapeutics in a research note on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, September 25th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Cowen reiterated a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Wednesday, December 6th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and an average target price of $28.82.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/05/private-asset-management-inc-boosts-position-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.